Methods of stratifying patients for treatment with retinoic acid receptor-alpha agonists

Patent metadata

Field	Value
Publication number	US-10240210-B2
Application number	US-201715828719-A
Country	US
Kind code	B2
Filing date	Dec 1, 2017
Priority date	Apr 8, 2016
Publication date	Mar 26, 2019
Grant date	Mar 26, 2019

Abstract

Described herein are methods that define cellular populations that are sensitive to RARA agonists and identify patient populations that will benefit from treatment with RARA agonists. The methods may comprise administering RARA agonists to patient populations.

First claim

The invention claimed is:

1. A method of treating a disease or condition selected from the group consisting of non-acute promyelocytic leukemia acute myelogenous leukemia (non-APL AML) and myelodysplastic syndrome (MDS) in a subject, the method comprising a step of:
administering effective amounts of tamibarotene and azacitidine in combination to the subject, wherein, prior to administration, a PBMC sample or an enriched PBMC sample from the subject has been determined to have at least one of:
(i) an elevated RARA mRNA level relative to a threshold level determined by RARA mRNA levels observed in comparable samples from a population of subjects having the same disease or condition as the subject, wherein the RARA mRNA is transcribed from a RARA gene that encodes a functional retinoic acid receptor-α and specifically excludes gene fusions that comprise all or a portion of the RARA gene; or
(ii) an elevated IRF8 mRNA level relative to a threshold level determined by IRF8 mRNA levels observed in comparable samples from a population of subjects having the same disease or condition as the subject.

2. A method of treating a disease or condition selected from the group consisting of non-acute promyelocytic leukemia acute myelogenous leukemia (non-APL AML) and myelodysplastic syndrome (MDS) in a subject, the method comprising a step of:
administering an effective amount of tamibarotene to a subject that is
(i) suffering from non-APL AML or MDS; and
(ii) receiving azacitidine;

wherein, prior to administration of the tamibarotene, a PBMC sample or an enriched PBMC sample from the subject has been determined to have at least one of:
(a) an elevated RARA mRNA level relative to a threshold level determined by RARA mRNA levels observed in comparable samples from a population of subjects having the same disease or condition as the subject, wherein the RARA mRNA is transcribed from a RARA gene that encodes a functional retinoic acid receptor-α and specifically excludes gene fusions that comprise all or a portion of the RARA gene; or
(b) an elevated IRF8 mRNA level relative to a threshold level determined by IRF8 mRNA levels observed in comparable samples from a population of subjects having the same disease or condition as the subject.

3. A method of treating a disease or condition selected from the group consisting of non-acute promyelocytic leukemia acute myelogenous leukemia (non-APL AML) and myelodysplastic syndrome (MDS) in a subject, the method comprising a step of:
administering an effective amount of azacitidine to a subject that is
(i) suffering from non-APL AML or MDS; and
(ii) receiving tamibarotene;

wherein, prior to receiving tamibarotene, a PBMC sample or an enriched PBMC sample from the subject has been determined to have at least one of:
(a) an elevated RARA mRNA level relative to a threshold level determined by RARA mRNA levels observed in comparable samples from a population of subjects having the same disease or condition as the subject, wherein the RARA mRNA is transcribed from a RARA gene that encodes a functional retinoic acid receptor-α and specifically excludes gene fusions that comprise all or a portion of the RARA gene; or
(b) an elevated IRF8 mRNA level relative to a threshold level determined by IRF8 mRNA levels observed in comparable samples from a population of subjects having the same disease or condition as the subject.

4. The method of claim 1 , wherein the threshold level for RARA mRNA is a cutoff value and the threshold level for IRF8 mRNA is a cutoff value.

5. The method of claim 4 , wherein the cutoff value for IRF8 mRNA is based on a pre-determined prevalence cutoff.

6. The method of claim 5 , where the pre-determined prevalence cutoff is based on IRF8 enhancer strength.

7. The method of claim 1 , wherein the subject is determined to have both an elevated RARA mRNA level and an elevated IRF8 mRNA level relative to their respective threshold levels.

8. The method of claim 1 , wherein the disease or condition is non-APL AML.

9. The method of claim 1 , wherein the disease or condition is MDS.

10. The method of claim 1 , wherein each of the elevated RARA mRNA level and the elevated IRF8 mRNA level is independently determined using fluorescent hybridization, PCR, qPCR, qRT-PCR, RNA sequencing, RNA hybridization and signal amplification or northern blot.

11. The method of claim 10 , wherein the elevated RARA mRNA level and the elevated IRF8 mRNA level are determined using qPCR.

12. The method of claim 2 , wherein the threshold level for RARA mRNA is a cutoff value and the threshold level for IRF8 mRNA is a cutoff value.

13. The method of claim 12 , wherein the cutoff value for IRF8 mRNA is based on a pre-determined prevalence cutoff.

14. The method of claim 13 , where the pre-determined prevalence cutoff is based on IRF8 enhancer strength.

15. The method of claim 2 , wherein the subject is determined to have both an elevated RARA mRNA level and an elevated IRF8 mRNA level relative to their respective threshold levels.

16. The method of claim 2 , wherein the disease or condition is non-APL AML.

17. The method of claim 2 , wherein the disease or condition is MDS.

18. The method of claim 2 , wherein each of the elevated RARA mRNA level and the elevated IRF8 mRNA level is independently determined using fluorescent hybridization, PCR, qPCR, qRT-PCR, RNA sequencing, RNA hybridization and signal amplification or northern blot.

19. The method of claim 18 , wherein the elevated RARA mRNA level and the elevated IRF8 mRNA level are determined using qPCR.

20. The method of claim 3 , wherein the threshold level for RARA mRNA is a cutoff value and the threshold level for IRF8 mRNA is a cutoff value.

21. The method of claim 20 , wherein the cutoff value for IRF8 mRNA is based on a pre-determined prevalence cutoff.

22. The method of claim 21 , where the pre-determined prevalence cutoff is based on IRF8 enhancer strength.

23. The method of claim 3 , wherein the subject is determined to have both an elevated RARA mRNA level and an elevated IRF8 mRNA level relative to their respective threshold levels.

24. The method of claim 3 , wherein the disease or condition is non-APL AML.

25. The method of claim 3 , wherein the disease or condition is MDS.

26. The method of claim 3 , wherein each of the elevated RARA mRNA level and the elevated IRF8 mRNA level is independently determined using fluorescent hybridization, PCR, qPCR, qRT-PCR, RNA sequencing, RNA hybridization and signal amplification or northern blot.

27. The method of claim 26 , wherein the elevated RARA mRNA level and the elevated IRF8 mRNA level are determined using qPCR.

Assignees

• Syros Pharmaceuticals Inc

Inventors

• Mckeown Michael Robert
• Fiore Christopher
• Eaton Matthew Lucas
• Lee Emily Payton
• Fritz Christian

Classifications

• C12Q2600/158

  Expression markers · CPC title

• A61K31/192

  having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid  {(cannabinoids A61K31/658)} · CPC title

• C12Q2600/106

  Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• C12Q1/6886 Primary

  for cancer (immunoassay for cancer G01N33/575) · CPC title